Pembrolizumab (Keytruda) Market: Navigating The Patent Cliff And Strategic Implications

Report Overview

Pembrolizumab (Keytruda), developed by Merck & Co., has transformed the oncology landscape as a PD‑1 immune checkpoint inhibitor approved for multiple cancers, including NSCLC, melanoma, head and neck squamous cell carcinoma, and urothelial carcinoma. With global revenues exceeding USD 29 billion in 2024, Keytruda stands as one of the highest‑grossing drugs worldwide. However, the approaching patent cliff with major U.S. patent expiry anticipated in 2028 and European protection extending until 2030-2031 signals significant shifts ahead. This transition presents challenges such as biosimilar competition and pricing erosion, but also opportunities in lifecycle management, novel formulations, and next‑generation immunotherapies. 

Key Report Deliverables

• A detailed analysis of the Keytruda market landscape, covering revenue size, oncology growth drivers, global adoption trends, and the evolving competitive context shaping the immuno-oncology industry.

• Forecasts evaluating post-patent market growth trajectories, expected biosimilar entry timelines across regions, and the projected impact on revenue streams, pricing dynamics, and market access in oncology.

• Identification of regulatory and market barriers affecting biosimilar penetration, including approval complexities, interchangeability requirements, pricing policies, and payer-driven access restrictions in different geographies worldwide.

• Comprehensive competitive landscape overview, highlighting direct PD-1/PD-L1 rivals, emerging pipeline candidates, next-generation immunotherapies, and the innovation strategies shaping the oncology therapeutic ecosystem.

• Strategic implications for Merck & Co. and competitors, focusing on lifecycle management, combination regimens, innovation pipelines, pricing strategies, and regional positioning to sustain leadership post-patent. 

Current Market Scenarios 

Keytruda continues to benefit from broad patent protection and regulatory exclusivities across major global markets, though expiry timelines vary significantly by region. In the U.S, primary exclusivity is expected to end in 2028, opening the door for biosimilar entry. In Europe, supplementary protection certificates could extend coverage until 2030-2031, granting Merck a longer period of defense. Japan and Canada follow similar schedules, while China and India are poised for earlier exposure to biosimilar challenges due to local legal disputes and comparatively weaker patent enforcement. This uneven schedule sets the stage for region-specific competitive and pricing dynamics.

The U.S. market, representing Keytruda’s single largest revenue contributor, will face substantial disruption once biosimilars enter, with expectations of steep price erosion and significant shifts in competitive positioning. Europe, with its cost-sensitive national health systems, is expected to embrace biosimilar adoption rapidly once protections expire, intensifying downward pricing pressure. In China and India, domestic biosimilar developers are already advancing toward launch, supported by government initiatives to increase affordability. Conversely, Japan, despite its high market value, will likely experience delayed biosimilar uptake due to stringent regulatory scrutiny and slower clinical acceptance, creating uneven adoption patterns across the Asia-Pacific region.

Despite looming patent expiry, Keytruda’s demand remains resilient as PD-1 inhibitors expand into earlier therapies, broader indications, and standard guidelines. Supported by real-world evidence, innovation, and combination regimens, the global immuno-oncology market will continue growing, with Keytruda sustaining a pivotal role despite biosimilar competition and pricing pressures worldwide.

Market Dynamics 

Growing Demand for Immuno-Oncology Therapies

The global rise in cancer prevalence, coupled with continued approvals for checkpoint inhibitors, fuels demand for PD-1 therapies. Keytruda has become a first-line standard across multiple tumor types, highlighting its clinical value. Its broad adoption and expanding use in earlier treatment lines secure a central role in oncology, reinforcing strong and sustained demand worldwide.

Pricing and Market Erosion Post-Patent

The expiration of Keytruda’s patents will open the market to biosimilar competitors, introducing significant downward pricing pressure. While oncology biosimilars may initially encounter adoption barriers due to clinical caution, payers and governments will increasingly drive cost-effective alternatives. This will accelerate biosimilar uptake, particularly in Europe, India, and China, reshaping market dynamics and reducing Merck’s market exclusivity advantage.

Opportunities in Lifecycle Management

Merck is actively defending Keytruda’s market position through subcutaneous formulations, broader indications, and innovative combination regimens. Beyond lifecycle extensions, the company is investing in next-generation immuno-oncology assets, including bispecific antibodies and cell therapies, which provide promising growth avenues. These strategies are designed to sustain revenue streams and strengthen Merck’s long-term leadership despite intensifying biosimilar competition.

Regional Divergence

Post-patent impacts will differ regionally: mature markets (U.S., EU, Japan) will see slower biosimilar adoption due to strict regulations and cautious uptake, while emerging markets (China, India, Latin America) will transition faster, driven by affordability, incentives, and cost-focused healthcare priorities.

The Pressure of Pricing and Market Erosion Post-Patent

The expiration of the Keytruda patent will trigger heightened competition from pembrolizumab biosimilars, profoundly influencing pricing dynamics and market share distribution in oncology. In the post-patent environment, downward pricing pressure is inevitable, particularly in price-sensitive markets where payers emphasize cost-effective cancer care. As lower-cost alternatives emerge, Merck’s market share will erode, with patients and providers increasingly considering affordable substitutes. However, oncology biosimilars typically face initial adoption barriers due to concerns around clinical comparability and therapeutic outcomes. 

The regulatory approval process will shape the pace of biosimilar entry. In mature markets such as the U.S. and EU, stringent clinical and regulatory requirements may delay penetration, though competition will intensify once approvals are secured. In contrast, Canada, India, and China are positioned for earlier biosimilar launches, driven by favorable regulatory pathways and domestic manufacturer activity. These regions are likely to experience faster pricing erosion and market share shifts. 

The entry of biosimilars will also raise clinical confidence concerns, as oncologists may be cautious about switching patients solely on price considerations, especially for life-saving cancer therapies. Nevertheless, payer policies, tender systems, and cost-containment measures will ultimately accelerate adoption, reshaping the competitive landscape. Over time, biosimilars will normalize oncology pricing, forcing Merck and competitors to differentiate through innovation, lifecycle strategies, and patient-centric value propositions.

“Innovating Beyond the Patent - Unlocking Future Growth Paths”

Despite the unavoidable biosimilar competition following Keytruda’s loss of exclusivity, the market will continue to present meaningful growth opportunities. One of the most significant lies in the development of next-generation formulations, including subcutaneous Keytruda, which could improve convenience and expand patient adoption. Additionally, ongoing research into combination regimens-pairing PD-1 inhibitors with targeted therapies, chemotherapy, or novel immunotherapies offers differentiated market positioning and reinforces Keytruda’s role in multi-modal cancer care. 

Innovation will also be critical in maintaining clinical relevance despite pricing pressures. Merck is advancing new immune-oncology assets such as bispecific antibodies and cell therapies, which can extend its leadership beyond PD-1 inhibitors. Meanwhile, the rise of biosimilars may also create market access opportunities in emerging economies, where affordability has been a key barrier. By leveraging authorized biosimilars or partnerships, Merck could expand treatment access while preserving brand presence. 

Another important growth driver lies in the expansion into emerging markets where cancer incidence is rising rapidly. Countries across Asia, Latin America, and Africa are seeing increasing demand for effective oncology treatments. As healthcare systems strengthen, there will be greater emphasis on cost-effective immunotherapies. Ensuring availability of both branded and affordable alternatives will allow broader patient access and sustain Keytruda’s strategic relevance in the global oncology market. 

“Shaping the Future - Biosimilars, Patient-Centric Models, and Regional Shifts”

• Shift Towards Patient-Centric Oncology Treatments

  There is a growing emphasis on patient-centric cancer therapies, focusing on convenience, quality of life, and sustained outcomes. Innovations such as subcutaneous Keytruda formulations and combination regimens tailored to tumor biology enhance treatment personalization. These approaches address multiple patient needs simultaneously, reinforcing the relevance of PD-1 inhibitors in delivering comprehensive oncology care, even amid biosimilar competition.

• Adoption of Value-Based Healthcare Models

  The global transition toward value-based healthcare is accelerating, with cost-effectiveness and measurable patient outcomes guiding treatment choices. This model will encourage the uptake of oncology biosimilars, particularly in price-sensitive markets where healthcare budgets face strain. Payers and providers will increasingly prioritize therapies that maintain clinical efficacy while delivering cost savings, reshaping competitive dynamics for Keytruda and its biosimilar challengers.

• Regional Divergence in Competitive Dynamics

  Following Keytruda’s patent expiry, regional variations will strongly shape adoption trends. In mature markets such as the U.S. and EU, biosimilar uptake may progress slowly due to regulatory caution and prescriber hesitancy. In contrast, emerging markets like China, India, and Brazil will transition faster, driven by affordability pressures, supportive government policies, and streamlined biosimilar approval processes.  

Overview of Alternative Therapeutics 

Keytruda faces direct competition from other PD-1/PD-L1 inhibitors such as Opdivo (BMS), Tecentriq (Roche), Imfinzi (AstraZeneca), and Libtayo (Sanofi/Regeneron). These agents are expanding their indications, combination regimens, and geographic reach to capture larger shares of the immuno-oncology market. Beyond PD-1 therapies, emerging innovations including TIGIT inhibitors like tiragolumab, bispecific antibodies such as glofitamab, and CAR-T therapies are shaping future treatment landscapes and increasing competitive pressures. A wave of pembrolizumab biosimilars is advancing through global clinical programs, led by manufacturers including Samsung Bioepis, Amgen, and multiple Indian companies. These entrants are preparing for market launches once U.S. patents expire in 2028. Their ability to gain traction will hinge on demonstrating clinical comparability, securing regulatory approvals, achieving cost advantages, and leveraging pricing strategies to penetrate oncology markets where affordability and payer acceptance strongly influence adoption.

Competitive Landscape

The competitive landscape for Pembrolizumab (Keytruda) is evolving rapidly, with major players pursuing diverse strategies to sustain leadership as the patent cliff approaches. Merck & Co., the dominant player, continues to leverage Keytruda’s broad label portfolio and lifecycle management initiatives, including the development of a subcutaneous formulation and expanded combination regimens. However, rivals such as Bristol Myers Squibb’s Opdivo, Roche’s Tecentriq, AstraZeneca’s Imfinzi, and Sanofi/Regeneron’s Libtayo are aggressively broadening indications and geographic reach, intensifying competition in the immuno-oncology market. 

On the indirect competition front, biosimilars are advancing quickly. Companies including Samsung Bioepis, Amgen, and several Indian manufacturers are conducting clinical programs to prepare for launches post-2028. China-based innovators such as Innovent (Tyvyt) and Junshi (Toripalimab) are strengthening local competition, with government backing accelerating their adoption in Asian markets. Additionally, next-generation therapies such as TIGIT inhibitors, bispecific antibodies, and CAR-T treatments remain in development but represent significant longer-term competitive pressures due to promising efficacy and novel mechanisms of action. 

As the market shifts, key players are employing proactive strategies to safeguard their positions. Merck is prioritizing lifecycle extensions, global collaborations, and patient-support initiatives, while competitors emphasize pipeline diversification and digital health platforms to reinforce engagement. The introduction of biosimilars and next-generation immunotherapies, especially in emerging regions, is expected to drive pricing pressure, expand accessibility, and reshape treatment paradigms. Ultimately, companies’ ability to innovate, differentiate, and deliver patient-centric solutions will determine their resilience in navigating the post-patent oncology landscape. 

North America Pembrolizumab (Keytruda) Market

North America remains the largest market for Keytruda, driven primarily by the United States, where the drug accounts for the majority of Merck’s oncology revenues. Patent exclusivity in the U.S. is expected to expire in 2028, creating opportunities for biosimilar pembrolizumab to enter and disrupt pricing. The U.S. market will likely undergo significant shifts post-expiry, with payers favoring more cost-effective options. In Canada, where exclusivity also ends in the late 2020s, biosimilars may arrive sooner, intensifying competition. While regulatory hurdles could delay immediate penetration, the region is expected to see substantial price erosion once biosimilars establish clinical and payer confidence. 

Europe Pembrolizumab (Keytruda) Market

The European Keytruda market is strong, with Germany, France, and the U.K. being the largest contributors. Patent protections, supported by Supplementary Protection Certificates (SPCs), extend exclusivity until 2030-2031, giving Merck a slightly longer runway compared to North America. However, once biosimilars gain approval, Europe’s cost-conscious healthcare systems are expected to prioritize switching to lower-cost alternatives. The region’s regulatory approval process for oncology biosimilars is stringent, which may delay immediate adoption, but when approved, competitive pricing pressures and tender-based procurement systems will rapidly reshape market share dynamics in favor of biosimilars. 

Asia Pacific Pembrolizumab (Keytruda) Market

The Asia Pacific region offers significant growth opportunities, especially in China, India, and Japan, where cancer incidence continues to rise. China is likely to see earlier biosimilar entry due to ongoing local patent challenges and strong support for domestic immunotherapies, creating heightened competition. In India, where affordability is crucial, biosimilars are expected to gain rapid traction once exclusivity lapses. Japan, however, with its stringent regulatory requirements, may see slower biosimilar adoption despite high demand for immuno-oncology therapies. Overall, the region presents substantial growth but also notable challenges, as regulatory approval timelines and local competition will strongly influence Keytruda’s market trajectory. 

Latin America Pembrolizumab (Keytruda) Market

In Latin America, the prevalence of cancer is steadily increasing, driving demand for immuno-oncology treatments such as Keytruda. Countries including Brazil, Mexico, and Argentina are the key markets, but affordability challenges remain central to adoption. With patent expirations approaching, the region is likely to see wider biosimilar availability, which will reduce prices and improve access. Regulatory agencies in Brazil and Mexico may facilitate faster biosimilar approvals, accelerating competitive dynamics. However, logistical barriers and healthcare infrastructure limitations could restrict penetration in certain areas, making pricing and distribution strategies critical for both Merck and biosimilar developers. 

Middle East and Africa Pembrolizumab (Keytruda) Market

The Middle East and Africa (MEA) market for Keytruda is emerging, with relatively lower penetration compared to developed regions. Key markets include Saudi Arabia, the UAE, and South Africa, where demand for oncology treatments is rising due to increasing cancer incidence. However, the region remains highly cost-sensitive, and the high price of branded Keytruda limits widespread access. The introduction of biosimilars post-patent expiry will be essential for expanding availability. Regulatory pathways differ across countries while the UAE and Saudi Arabia offer more efficient approval processes, other nations may experience delays. Nevertheless, improving healthcare infrastructure and access will drive long-term expansion. 

Analyst Perspective

The Keytruda market is approaching a pivotal transition as its primary patents near expiration, beginning in the U.S. in 2028 and in Europe by 2030-2031. Currently dominated by Merck & Co., the market will face increasing competition from pembrolizumab biosimilars, which will drive substantial price reductions and market share shifts. At the same time, rival PD-1/PD-L1 inhibitors such as Opdivo, Tecentriq, Imfinzi, and Libtayo-along with next-generation immuno-oncology therapies like TIGIT inhibitors and bispecific antibodies, are set to intensify competitive pressures, particularly in price-sensitive regions. Despite these challenges, demand for PD-1 inhibitors will remain strong, supported by their proven efficacy, expanding indications, and continued integration into oncology treatment guidelines. To sustain competitiveness, Merck and other players must prioritize lifecycle innovation, real-world evidence generation, and patient-centric value strategies in navigating this evolving oncology landscape.

Case Study (Recent Engagement): Keytruda Patent-Cliff & Price-Erosion Impact Model

PROJECT OBJECTIVE

To evaluate the potential revenue, price, and patient access implications of Keytruda’s 2028 patent cliff, incorporating biosimilar entry dynamics, country-specific adoption curves, and Merck’s lifecycle defense strategies (remarkably the subcutaneous formulation). The goal was to provide the client with a transparent, scenario-based model to anticipate outcomes and inform strategy.

GVR SOLUTION

• Built a bottom-up commodity-flow and analogue-based model, anchored on Merck’s $29.5B Keytruda sales in 2024.

• Integrated jurisdictional LOE timelines (EU mid-2028, U.S. 2028-2029 pending litigation outcomes).

• Modeled biosimilar adoption S-curves calibrated to oncology antibody analogues (EU faster via tenders, U.S. slower via contracting).

• Applied price-erosion benchmarks (EU -15-30% Yr-1, deepening to -45-60% by Yr-3; U.S. -10-25% net decline over same horizon).

• Layered lifecycle defenses (SC uptake assumptions of 25-40% of innovator units, combo refresh, contracting) to quantify buffers.

• Delivered outputs as a dynamic Excel scenario tool and a management-ready PPT deck with revenue bridges, sensitivity tornadoes, and SC migration visuals.

IMPACT FOR CLIENT

• Enabled the client to quantify downside vs. defense-optimized revenue trajectories:

  • Base case: 30-40% global revenue decline by Year-3 post-LOE.

  • Downside: 45-55% decline in tender-heavy markets.

  • Defense-optimized: Contained erosion to ~-20-25% with strong SC adoption.

• Gave the client a clear view of which markets drive early erosion (EU) and where strategic contracting or SC migration can preserve share (U.S.).

• Equipped decision-makers with a playbook of watch-points (tender concentration, litigation outcomes, SC IP coverage, combo pipeline) to guide commercial strategy.

• Provided a transparent methodology that could be presented to boards/investors with evidence-backed assumptions

WHY THIS MATTERS

• Keytruda is the world’s best-selling cancer drug, representing nearly one-third of Merck’s revenue.

• Patent expiry will reshape both Merck’s earnings profile and global oncology access dynamics.

• Payers and governments stand to benefit from biosimilar entry through lower costs, but manufacturers need to manage cliff risk while capturing upside from lifecycle innovations.

• Understanding how quickly revenues erode and how patient access expands post-biosimilar is critical for:

  • Biopharma companies (strategic planning, pipeline prioritization).

  • Investors (valuing Merck’s cash flows beyond 2028).

  • Payers and policymakers (budgeting for oncology drug spend).

• A robust patent cliff model helps clients navigate the dual challenge of price erosion and patient expansion, ensuring strategies are grounded in real-world benchmarks.